update from barda, page-11

This comment is quite interesting:

"we are considering what is the best next step for the Biota project and the overall influenza antiviral drug development program before going forward with clinical studies in the Southern Hemisphere and manufacturing optimization and validation."

Perhaps:

- smaller trials
- fast-track due to cost of lengthy trials
- acceptance of some overseas compliancies (e.g. Japan or EU) so as not to double-up on costs and times in bringing drugs to market

Yes, new commercially savvy personnel at HHS and more awareness of the importance of grant funding achieving desired results with less red-tape and more commonsense. Biota and LANI could be right in the thick of some groundbreaking changes, leading, ultimately to quicker to market.